In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media reports. Citing ...
Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable effect for a drug that ...
Jeffrey Hatcher's adaptation of Patrick Hamilton's "Rope's End" reverts from realism and instead uses a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback